Open-label, Multicenter, Phase II Immunotherapy Study With Racotumomab in Patients With High-risk Neuroblastoma
Latest Information Update: 15 Sep 2023
At a glance
- Drugs Racotumomab (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- Sponsors Elea
- 07 Sep 2023 Status changed from active, no longer recruiting to completed.
- 30 Sep 2021 Status changed from recruiting to active, no longer recruiting.
- 16 Sep 2021 Planned End Date changed from 1 Jun 2021 to 1 Sep 2022.